Celadon Pharmaceuticals (CEL) Competitors GBX 19.88 +2.28 (+12.93%) (As of 10:49 AM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlines CEL vs. CNSL, FOX, OTT, BCE, CZN, CHT, DVW, BRCI, NPT, and RCIShould you be buying Celadon Pharmaceuticals stock or one of its competitors? The main competitors of Celadon Pharmaceuticals include Cambridge Nutritional Sciences (CNSL), Fox Marble (FOX), Oxford Technology 3 Venture Capital Trust (OTT), Beacon Energy (BCE), Curzon Energy (CZN), 290005 (CHT.L) (CHT), 5008 (DVW.L) (DVW), BlackRock Comms Income Inv Tst (BRCI), NetPlay TV (NPT), and RapidCloud International (RCI). These companies are all part of the "communication" industry. Celadon Pharmaceuticals vs. Cambridge Nutritional Sciences Fox Marble Oxford Technology 3 Venture Capital Trust Beacon Energy Curzon Energy 290005 (CHT.L) 5008 (DVW.L) BlackRock Comms Income Inv Tst NetPlay TV RapidCloud International Celadon Pharmaceuticals (LON:CEL) and Cambridge Nutritional Sciences (LON:CNSL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, community ranking, earnings, profitability, institutional ownership, media sentiment, valuation and risk. Which has preferable earnings & valuation, CEL or CNSL? Cambridge Nutritional Sciences has higher revenue and earnings than Celadon Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCeladon Pharmaceuticals£11.26K1,117.08-£5.23M-£0.08-228.33Cambridge Nutritional Sciences£9.77M0.73-£3.03MN/AN/A Which has more volatility & risk, CEL or CNSL? Celadon Pharmaceuticals has a beta of -0.26, indicating that its stock price is 126% less volatile than the S&P 500. Comparatively, Cambridge Nutritional Sciences has a beta of 3.89, indicating that its stock price is 289% more volatile than the S&P 500. Is CEL or CNSL more profitable? Celadon Pharmaceuticals has a net margin of 0.00% compared to Cambridge Nutritional Sciences' net margin of -3.36%. Cambridge Nutritional Sciences' return on equity of -3.34% beat Celadon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Celadon PharmaceuticalsN/A -190.71% -34.40% Cambridge Nutritional Sciences -3.36%-3.34%-2.36% Do institutionals and insiders believe in CEL or CNSL? 10.7% of Celadon Pharmaceuticals shares are owned by institutional investors. Comparatively, 10.2% of Cambridge Nutritional Sciences shares are owned by institutional investors. 65.1% of Celadon Pharmaceuticals shares are owned by insiders. Comparatively, 10.9% of Cambridge Nutritional Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media refer more to CEL or CNSL? In the previous week, Celadon Pharmaceuticals had 1 more articles in the media than Cambridge Nutritional Sciences. MarketBeat recorded 1 mentions for Celadon Pharmaceuticals and 0 mentions for Cambridge Nutritional Sciences. Celadon Pharmaceuticals' average media sentiment score of 0.00 equaled Cambridge Nutritional Sciences'average media sentiment score. Company Overall Sentiment Celadon Pharmaceuticals Neutral Cambridge Nutritional Sciences Neutral Does the MarketBeat Community prefer CEL or CNSL? Celadon Pharmaceuticals received 4 more outperform votes than Cambridge Nutritional Sciences when rated by MarketBeat users. CompanyUnderperformOutperformCeladon PharmaceuticalsOutperform Votes4100.00% Underperform VotesNo VotesCambridge Nutritional SciencesN/AN/A SummaryCeladon Pharmaceuticals beats Cambridge Nutritional Sciences on 7 of the 12 factors compared between the two stocks. Ad Awesomely, LLCSocial Security Alternative (collect now)Would you like to lock in up to 25 years of retirement income? Because all it takes less than 30 minutes to jump through this secret banking loophole that could make that happen for less than a single $100 billClick Here for Details. Get Celadon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CEL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CEL vs. The Competition Export to ExcelMetricCeladon PharmaceuticalsDrug Manufacturers IndustryMedical SectorLON ExchangeMarket Cap£12.58M£1.20B£4.94B£1.42BDividend YieldN/A3.13%7.65%11.72%P/E Ratio-228.3393.6781.941,570.11Price / Sales1,117.082,245.771,351.81255,511.20Price / Cash3.0510.0234.4432.92Price / Book4.573.084.732.90Net Income-£5.23M£138.28M£113.08M£152.61M7 Day Performance46.13%23.82%6.40%8.49%1 Month Performance-31.07%2,055.67%121.95%16.61%1 Year Performance-81.91%2,084.63%158.43%18.78% Celadon Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CELCeladon PharmaceuticalsN/AGBX 19.88+12.9%N/A-82.6%£13.68M£11,258.00-248.442,780CNSLCambridge Nutritional SciencesN/AGBX 3.20+3.2%N/A+17.0%£7.61M£9.77M-362.103,200FOXFox MarbleN/AGBX 1.35+14.9%N/A+0.0%£5.63M£722,064.00-135.0010,600OTTOxford Technology 3 Venture Capital TrustN/AGBX 34-19.4%N/AN/A£2.13M£-85,000.00-12.59203Gap DownBCEBeacon EnergyN/AGBX 0flatN/A-97.0%£555,000.00N/A-0.3544,600CZNCurzon EnergyN/AGBX 0.03+21.4%N/AN/A£34,000.00N/A-3.4014,700Gap DownCHT290005 (CHT.L)N/AN/AN/AN/A£0.00N/A0.0020,300DVW5008 (DVW.L)N/AN/AN/AN/A£0.00N/A0.00N/AGap UpBRCIBlackRock Comms Income Inv TstN/AGBX 70.60-1.0%N/A+0.0%£0.00N/A0.00N/AHigh Trading VolumeNPTNetPlay TVN/AN/AN/AN/A£0.00N/A0.00147,000RCIRapidCloud InternationalN/AN/AN/AN/A£0.00N/A0.0023,000 Related Companies and Tools Related Companies Cambridge Nutritional Sciences Competitors Fox Marble Competitors Oxford Technology 3 Venture Capital Trust Competitors Beacon Energy Competitors Curzon Energy Competitors 290005 (CHT.L) Competitors 5008 (DVW.L) Competitors BlackRock Comms Income Inv Tst Competitors NetPlay TV Competitors RapidCloud International Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:CEL) was last updated on 12/9/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe Crypto Secret Wall Street Doesn’t Want You to KnowThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWaveBot: The Automated Trading Tool for This Bull MarketThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celadon Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Celadon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
